Skip to main content
PEPTARA LABS
Get Started

Tirzepatide Results Timeline

Tirzepatide Results Timeline: What Trials Measured

Published by · Updated · How we research and check our pages

The short answer

The tirzepatide results timeline from the SURMOUNT-1 trial ran 72 weeks, and in the highest dose group, group-mean body weight fell up to about 22.5 percent (Jastreboff et al., NEJM 2022). The curve fell fastest in the early months, then kept declining more slowly, with most groups reaching a plateau somewhere between about 24 and 36 weeks (Horn et al., Clinical Obesity 2025). These are group averages from controlled trials, not a personal forecast.

This page is general educational information, research-use framing only, not medical advice. Research-grade tirzepatide is supplied for laboratory research only, not for human use.

What does the tirzepatide results timeline look like over 72 weeks?

In SURMOUNT-1, group-mean body weight fell steadily across a 72-week period, reaching up to about 22.5 percent in the highest dose group (Jastreboff et al., NEJM 2022; doi:10.1056/NEJMoa2206038).

SURMOUNT-1 enrolled 2,539 adults with obesity or overweight who did not have type 2 diabetes. The trial compared three tirzepatide dose groups against placebo, all alongside lifestyle guidance, over 72 weeks. The result was dose dependent: higher dose groups produced larger average reductions.

The trial reported two sets of figures. The efficacy estimand estimates the effect if people stayed on treatment. The treatment-regimen estimand includes everyone as assigned, even those who stopped early, so its numbers are a little smaller. Both are shown below (Jastreboff et al., NEJM 2022).

Tirzepatide dose group (SURMOUNT-1)Mean weight change at week 72, treatment-regimen estimandMean weight change at week 72, efficacy estimandSource
Placeboabout -3.1 percentabout -2.4 percentJastreboff et al., NEJM 2022
Lowest dose groupabout -15.0 percentabout -16.0 percentJastreboff et al., NEJM 2022
Middle dose groupabout -19.5 percentabout -21.4 percentJastreboff et al., NEJM 2022
Highest dose groupabout -20.9 percentabout -22.5 percentJastreboff et al., NEJM 2022

Figures are group means from a controlled trial, reported here for education.

When did most of the weight loss happen during the trial?

The reported mean curves fell most steeply in the early months, then kept declining at a slower pace through the rest of the 72 weeks (Jastreboff et al., NEJM 2022; Horn et al., Clinical Obesity 2025).

The group-mean weight line dropped fastest in the early months. A later analysis of the SURMOUNT trials reported that mean weight reduction in the first 24 weeks was about 13 to 15 percent across groups, with meaningful additional loss between weeks 24 and 72 (Horn et al., Clinical Obesity 2025; doi:10.1111/cob.12734). As the trial went on, the average line kept trending downward but flattened gradually. That shape, quick early change followed by a longer, slower decline, is why a timeline is a curve, not a straight line.

Timeline milestoneReported group-mean weight changeSource
First 24 weeksabout 13 to 15 percent across dose groupsHorn et al., Clinical Obesity 2025
Week 72, highest dose groupup to about 22.5 percentJastreboff et al., NEJM 2022
Median time to plateauabout 24 to 36 weeks, by starting BMIHorn et al., Clinical Obesity 2025

These milestones restate figures reported elsewhere on this page; each is a group mean from a controlled trial, shown for education, not as a personal forecast.

What is a weight-loss plateau, and when does it happen?

A plateau is the point where weight stops falling and holds steady; in the SURMOUNT trials the median time to plateau ranged from about 24 to 36 weeks depending on starting BMI (Horn et al., Clinical Obesity 2025).

Horn et al. (Clinical Obesity 2025) examined how long weight loss continued before it leveled off in SURMOUNT-1 and SURMOUNT-4. Across four BMI categories, the reported median time to weight plateau was about 24.3, 26.0, 36.1, and 36.1 weeks, with higher-BMI groups tending to keep losing longer. The reason a plateau arrives at all is physiology, not failure of the compound. As body weight drops, the body burns fewer calories at rest, a shift called adaptive thermogenesis, while appetite signals push back (Rosenbaum and Leibel, Int J Obes 2010; doi:10.1038/ijo.2010.184). Those forces slow the rate of loss until the timeline flattens.

What happens on the timeline after tirzepatide is withdrawn?

Trial data show substantial weight regain after tirzepatide is withdrawn, while continued treatment held the loss (Aronne et al., JAMA 2024).

SURMOUNT-4 used a 36-week open-label lead-in on tirzepatide, then randomized participants either to continue the compound or to switch to placebo for 52 more weeks. From randomization to week 88, the group that continued tirzepatide lost a further mean of about 5.5 percent, while the group switched to placebo regained a mean of about 14.0 percent, a between-group difference of about 19.4 percentage points (Aronne et al., JAMA 2024; doi:10.1001/jama.2023.24945). The same direction of effect appeared with semaglutide: in the STEP 1 trial extension, participants regained about two-thirds of their prior weight loss within a year of stopping (Wilding et al., Diabetes Obes Metab 2022; doi:10.1111/dom.14725). The timeline is not a one-way street; withdrawal reverses part of it.

How does the tirzepatide timeline compare with semaglutide?

In a head-to-head diabetes trial, tirzepatide produced greater weight reduction than semaglutide, and separate obesity trials report larger mean loss for tirzepatide, though the trials are not directly matched (Frias et al., NEJM 2021; Jastreboff et al., NEJM 2022; Wilding et al., NEJM 2021).

SURPASS-2 compared tirzepatide against semaglutide in 1,879 adults with type 2 diabetes over 40 weeks and found tirzepatide produced greater weight reduction (Frias et al., NEJM 2021; doi:10.1056/NEJMoa2107519). Note the caveats: that was a diabetes trial, the semaglutide comparator was the lower diabetes-trial dose rather than the obesity-trial dose, and populations differ. Comparing across separate obesity trials, tirzepatide's mean loss (up to about 22.5 percent, Jastreboff et al., NEJM 2022) ran higher than semaglutide's (up to about 15 percent on the treatment policy estimand, Wilding et al., NEJM 2021), but cross-trial numbers are not the same as a direct comparison.

TrialCompoundPopulationDurationGroup-mean weight changeSource
SURMOUNT-1tirzepatideobesity or overweight, no diabetes72 weeksup to about 22.5 percentJastreboff et al., NEJM 2022
STEP 1semaglutideobesity or overweight, no diabetes68 weeksup to about 15 percent (treatment policy estimand)Wilding et al., NEJM 2021
SURPASS-2tirzepatide vs semaglutide (lower, diabetes-trial dose)type 2 diabetes40 weeksgreater with tirzepatideFrias et al., NEJM 2021

Do group means predict individual outcomes?

No; these are reported group averages from controlled trials, and individual response varies widely.

A group mean is the average of many people. In the same trial, some participants lost far more than the average and some lost far less. Starting weight, adherence, dose, and the lifestyle support built into each trial all shaped the reported numbers.

Tirzepatide Results Timeline: FAQ

How long was the main tirzepatide weight-loss trial?

SURMOUNT-1 ran for 72 weeks in adults with obesity or overweight without diabetes (Jastreboff et al., NEJM 2022).

What was the highest reported average weight loss?

Group-mean body weight fell up to about 22.5 percent in the highest dose group (Jastreboff et al., NEJM 2022).

How many dose groups did SURMOUNT-1 compare?

Three tirzepatide dose groups against placebo (Jastreboff et al., NEJM 2022).

Did weight loss continue indefinitely in the tirzepatide trials?

No; loss slows and reaches a plateau over time, with a reported median around 24 to 36 weeks by starting BMI, as the body adapts (Horn et al., Clinical Obesity 2025; Rosenbaum and Leibel, Int J Obes 2010).

What happened when tirzepatide was withdrawn in trials?

Trial data show substantial regain after withdrawal, while continued treatment held the loss (Aronne et al., JAMA 2024); a comparable rebound of about two-thirds of prior loss within a year was seen with semaglutide (Wilding et al., Diabetes Obes Metab 2022).

Is tirzepatide stronger than semaglutide?

A head-to-head diabetes trial reported greater weight reduction with tirzepatide (Frias et al., NEJM 2021), and separate obesity trials show a higher mean for tirzepatide, but the trials are not directly matched (Jastreboff et al., NEJM 2022; Wilding et al., NEJM 2021).

Why does the rate of weight loss slow down?

The body lowers its resting energy use and increases appetite signals as weight drops, which blunts further loss (Rosenbaum and Leibel, Int J Obes 2010).

References

  1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038. PMID: 35658024.
  2. Horn DB, Kahan S, Batterham RL, et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clin Obes. 2025;15(3):e12734. doi:10.1111/cob.12734. PMID: 39800653.
  3. Rosenbaum M, Leibel RL. Adaptive thermogenesis in humans. Int J Obes (Lond). 2010;34 Suppl 1:S47-S55. doi:10.1038/ijo.2010.184. PMID: 20935667.
  4. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. doi:10.1001/jama.2023.24945. PMID: 38078870.
  5. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. doi:10.1111/dom.14725. PMID: 35441470.
  6. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519. PMID: 34170647.
  7. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183. PMID: 33567185.

Sourcing research-grade peptides?

Talk to the Peptara Labs team about purity, third-party certificates of analysis, and cold-chain shipping.

General educational information only, research-use framing, not medical advice. Research material is for laboratory research only, not for human use.

Chat with us